Risa Weisberg, PhD
Professor
Boston University Chobanian & Avedisian School of Medicine
Psychiatry
General Psychiatry

PhD, State University of New York at Albany
BA, Tufts University

Pronouns: she/her/hers



Risa B. Weisberg, PhD, is a Professor of Psychiatry at the Chobanian and Avedisian School of Medicine and an Adjunct Professor of Psychiatry and Family Medicine at the Alpert Medical School, Brown University. Additionally, Dr. Weisberg is the Chief Clinical and Scientific Officer of RealizedCare, a digital health company developing interventions for common behavioral health problems including chronic pain, substance use, anxiety, and depression.

Dr. Weisberg's research focuses on developing and testing behavioral health interventions that can be more easily implemented and scaled. Her work encompasses interventions for chronic pain, opioid use disorder, anxiety disorders, depression, chronic medical conditions, and sexual and reproductive health. Her treatment development and clinical trial work has been funded by the National Institute of Health, as well as by industry and foundation grants, for over 20 years. Currently, she is the principal investigator on a NIDA-funded clinical trial examining the effectiveness of a behavioral treatment for primary care patients with chronic pain and opioid use disorder. She has also served as PI and Co-Investigator on two large-scale, longitudinal studies, examining the nature and course of anxiety disorders; the Harvard/Brown Anxiety Research Project (HARP) and the Primary Care Anxiety Project (PCAP).

VA Boston Healthcare System




Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings
02/15/2019 - 01/31/2025 (Multi-PI)
PI: Risa Weisberg, PhD
NIH/National Institute on Drug Abuse
5R01DA045695-05

The impact of COVID-19-related medication assisted treatment policy changes on care and outcomes for patients with opioid use disorders
03/01/2021 - 09/15/2024 (PI of Sub-Project / SP)
Boston VA Research Institute, Inc. Patient-Cnt.Out. Res




Title


Yr Title Project-Sub Proj Pubs
2024 Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder 5R44DA053848-04
2023 Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder 5R44DA053848-03
2023 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings 5R01DA045695-05
2022 Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder 4R44DA053848-02
2022 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings 5R01DA045695-04
2021 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings 5R01DA045695-03
2020 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings 5R01DA045695-02
2019 Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings 1R01DA045695-01A1
2016 Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders 5R34MH097820-03 1
2015 Behavioral Consultation for HIV+ Older Adults Prescribed Opioids for Chronic Pain 5R21DA038203-02
Showing 10 of 25 results. Show All Results

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis       Copy PMIDs To Clipboard

  1. Moitra E, Stein MD, Busch AM, Pinkston MM, Bray JW, Abrantes AM, Baker JV, Weisberg RB, Anderson BJ, Uebelacker LA. Health Care Service Utilization Among People with HIV, Chronic Pain, and Depression: Utilization and Cost Outcomes from the HIV-PASS Study. AIDS Behav. 2024 Nov 15.View Related Profiles. PMID: 39546145
     
  2. Haley DF, Stein MD, Bendiks S, Karzhevsky S, Pierce C, Dunn A, Herman DS, Anderson B, Weisberg RB. Associations of discomfort intolerance, discomfort avoidance, and cannabis and alcohol use among persons with chronic pain receiving prescription buprenorphine for opioid use disorder. Drug Alcohol Depend. 2024 Oct 24; 265:112472.View Related Profiles. PMID: 39488941
     
  3. Garland EL, Recasens M, Taple BJ, Donaldson GW, Weisberg RB. Virtual reality-based Mindfulness-Oriented Recovery Enhancement (MORE-VR) as an adjunct to medications for opioid use disorder: a Phase 1 trial. Ann Med. 2024 Dec; 56(1):2392870. PMID: 39172534; PMCID: PMC11342816; DOI: 10.1080/07853890.2024.2392870;
     
  4. Stein MD, Bendiks S, Karzhevsky S, Pierce C, Dunn A, Majeski A, Herman DS, Weisberg RB. Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine. Contemp Clin Trials. 2024 Aug; 143:107608.View Related Profiles. PMID: 38878997
     
  5. LeBeau LS, White MC, Henke RM, Hyde J, Sarpong A, Weisberg RB, Livingston NA, Mulvaney-Day N. Considerations for Opioid Use Disorder Treatment From Policy Makers' Experiences With COVID-19 Policy Flexibilities. Psychiatr Serv. 2024 Jun 05; appips20230260.View Related Profiles. PMID: 38835255
     
  6. Shepardson RL, Weisberg RB, Wade M, Maisto SA, Funderburk JS. Brief modular anxiety intervention for primary care: Hybrid I pilot randomized controlled trial of feasibility, acceptability, effectiveness, and implementation potential. J Affect Disord. 2024 Sep 15; 361:497-507. PMID: 38810782
     
  7. Livingston NA, Sarpong A, Sistad R, Roth C, Banducci AN, Simpson T, Hyde J, Davenport M, Weisberg R. Gender differences in receipt of telehealth versus in person behavioral therapy, medication for opioid use disorder (MOUD), and 90-day MOUD retention during the pandemic: A retrospective veteran cohort study. J Subst Use Addict Treat. 2024 Jan; 156:209188.View Related Profiles. PMID: 37866437
     
  8. Uebelacker LA, Pinkston MM, Busch AM, Baker JV, Anderson B, Caviness CM, Herman DS, Weisberg RB, Abrantes AM, Stein MD. HIV-PASS (Pain and Sadness Support): Randomized Controlled Trial of a Behavioral Health Intervention for Interference Due to Pain in People Living With HIV, Chronic Pain, and Depression. Psychosom Med. 2023 Apr 01; 85(3):250-259.View Related Profiles. PMID: 36799731; PMCID: PMC10073275; DOI: 10.1097/PSY.0000000000001172;
     
  9. Livingston NA, Davenport M, Head M, Henke R, LeBeau LS, Gibson TB, Banducci AN, Sarpong A, Jayanthi S, Roth C, Camacho-Cook J, Meng F, Hyde J, Mulvaney-Day N, White M, Chen DC, Stein MD, Weisberg R. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study. Drug Alcohol Depend. 2022 Dec 01; 241:109678.View Related Profiles. PMID: 36368167; PMCID: PMC9624112; DOI: 10.1016/j.drugalcdep.2022.109678;
     
  10. Shepardson RL, Fletcher TL, Funderburk JS, Weisberg RB, Beehler GP, Maisto SA. Barriers to and facilitators of using evidence-based, cognitive-behavioral anxiety interventions in integrated primary care practice. Psychol Serv. 2023 Nov; 20(4):709-722. PMID: 35951391; PMCID: PMC10166237; DOI: 10.1037/ser0000696;
     
Showing 10 of 92 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 92 publications over 28 distinct years, with a maximum of 9 publications in 2014

YearPublications
19941
19951
19971
19991
20012
20023
20032
20044
20055
20064
20072
20081
20094
20105
20117
20125
20133
20149
20153
20164
20172
20183
20194
20201
20212
20225
20232
20246

2013 Anxiety and Depression Association of America: Member of Distinction
2004 NIH Complexities of Co-occurring Conditions: New Investigator Award
2002 NIH Summer Institute for Randomized Clinical Trials Involving Behavioral Intervention: Fellow
2001 Association for Clinical Psychosocial Research: Young Investigator Award
Contact for Mentoring:

150 S Huntington Avenue
Jamaica Plain MA 02130
Google Map


Weisberg's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_
Same Department